Zeroing in on neurodegenerative α-synuclein

Nat Rev Drug Discov. 2017 May 31;16(6):371-373. doi: 10.1038/nrd.2017.95.
No abstract available

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Drug Design*
  • Humans
  • Lewy Bodies / metabolism
  • Molecular Targeted Therapy
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • alpha-Synuclein / metabolism*

Substances

  • Antiparkinson Agents
  • alpha-Synuclein